NasdaqGM - Nasdaq Real Time Price USD
Axsome Therapeutics, Inc. (AXSM)
108.30
+0.77
+(0.72%)
At close: 4:00:00 PM EDT
109.27
+0.97
+(0.90%)
After hours: 6:21:35 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 11 | 11 | 10 | 11 |
| Avg. Estimate | -1.09 | -0.91 | -3.74 | 1.14 |
| Low Estimate | -1.21 | -1.34 | -4.45 | -2.97 |
| High Estimate | -0.85 | -0.52 | -2.58 | 4.8 |
| Year Ago EPS | -1.67 | -1.34 | -5.99 | -3.74 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 17 | 17 | 18 | 18 |
| Avg. Estimate | 140.02M | 162.56M | 613.49M | 979.62M |
| Low Estimate | 135.1M | 143.4M | 558.6M | 777.5M |
| High Estimate | 148.1M | 181.46M | 663.7M | 1.15B |
| Year Ago Sales | 87.17M | 104.76M | 385.69M | 613.49M |
| Sales Growth (year/est) | 60.64% | 55.17% | 59.06% | 59.68% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -1.33 | -1.39 | -1.04 | -1.35 |
| EPS Actual | -1.67 | -1.34 | -1.54 | -1.22 |
| Difference | -0.34 | 0.05 | -0.5 | 0.13 |
| Surprise % | -25.84% | 3.49% | -47.76% | 9.51% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -1.09 | -0.91 | -3.74 | 1.14 |
| 7 Days Ago | -1.08 | -0.92 | -3.73 | 1.26 |
| 30 Days Ago | -1.04 | -0.73 | -3.47 | 1.4 |
| 60 Days Ago | -1.12 | -0.8 | -3.71 | 1.43 |
| 90 Days Ago | -0.82 | -0.5 | -1.85 | 3.78 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 5 | -- |
| Up Last 30 Days | 5 | 4 | 5 | 5 |
| Down Last 7 Days | -- | -- | 3 | 1 |
| Down Last 30 Days | 4 | 5 | 3 | 3 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| AXSM | 34.96% | 32.43% | 37.62% | 130.42% |
| S&P 500 | 13.32% | 2.67% | 7.78% | 13.75% |
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/7/2025 |
| Maintains | Wells Fargo: Overweight to Overweight | 5/6/2025 |
| Maintains | Baird: Outperform to Outperform | 5/6/2025 |
| Maintains | RBC Capital: Outperform to Outperform | 4/29/2025 |
| Initiated | Jefferies: Buy | 4/7/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/3/2025 |
Related Tickers
IOVA Iovance Biotherapeutics, Inc.
1.8300
+10.24%
VKTX Viking Therapeutics, Inc.
27.50
-3.27%
MDGL Madrigal Pharmaceuticals, Inc.
290.72
-0.08%
TGTX TG Therapeutics, Inc.
34.98
+1.80%
VRTX Vertex Pharmaceuticals Incorporated
440.66
+0.46%
BHVN Biohaven Ltd.
15.75
-1.69%
ALT Altimmune, Inc.
5.50
-1.43%
BBIO BridgeBio Pharma, Inc.
33.69
-0.44%
AVXL Anavex Life Sciences Corp.
8.44
+1.44%
VRNA Verona Pharma plc
72.58
+1.78%